Noteworthy Disparate technologies meet in NeXagen-Vestar merger

Mergers can take many shapes, combining companies with overlapping technologies or those with disparate technologies and skills. Last week's deal between NeXagen Inc. and Vestar Corp. is one of the latter, melding NXGN's expertise in oligonucleotide drug discovery with VSTR's liposome drug delivery technology and infrastructure in manufacturing, clinical trials and marketing.

By bringing together two companies with little overlap, the formation of NeXstar Pharmaceuticals Inc. will improve prospects on both the product development and financial fronts, said NXGN CEO Patrick Mahaffy, who will retain that position at NeXstar.